Skip to main navigation Skip to search Skip to main content

Plasma Metabolomics Reveals Systemic Metabolic Alterations of Subclinical and Clinical Hypothyroidism

  • Feifei Shao (Co-first Author)
  • , Rui Li (Co-first Author)
  • , Qian Guo
  • , Rui Qin
  • , Wenxiu Su
  • , Huiyong Yin* (Co-last Author)
  • , Limin Tian* (Co-last Author)
  • *Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

54 Downloads (CityUHK Scholars)

Abstract

Context:  Clinical hypothyroidism (CH) and subclinical hypothyroidism (SCH) have been linked to various metabolic comorbidities but the underlying metabolic alterations remain unclear. Metabolomics may provide metabolic insights into the pathophysiology of hypothyroidism. Objective:  We explored metabolic alterations in SCH and CH and identify potential metabolite biomarkers for the discrimination of SCH and CH from euthyroid individuals. Methods:  Plasma samples from a cohort of 126 human subjects, including 45 patients with CH, 41 patients with SCH, and 40 euthyroid controls, were analyzed by high-resolution mass spectrometry-based metabolomics. Data were processed by multivariate principal components analysis and orthogonal partial least squares discriminant analysis. Correlation analysis was performed by a Multivariate Linear Regression analysis. Unbiased Variable selection in R algorithm and 3 machine learning models were utilized to develop prediction models based on potential metabolite biomarkers. Results:  The plasma metabolomic patterns in SCH and CH groups were significantly different from those of control groups, while metabolite alterations between SCH and CH groups were dramatically similar. Pathway enrichment analysis found that SCH and CH had a significant impact on primary bile acid biosynthesis, steroid hormone biosynthesis, lysine degradation, tryptophan metabolism, and purine metabolism. Significant associations for 65 metabolites were found with levels of thyrotropin, free thyroxine, thyroid peroxidase antibody, or thyroglobulin antibody. We successfully selected and validated 17 metabolic biomarkers to differentiate 3 groups. Conclusion:  SCH and CH have significantly altered metabolic patterns associated with hypothyroidism, and metabolomics coupled with machine learning algorithms can be used to develop diagnostic models based on selected metabolites. © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
Original languageEnglish
Pages (from-to)13-25
Number of pages13
JournalJournal of Clinical Endocrinology and Metabolism
Volume108
Issue number1
Online published1 Oct 2022
DOIs
Publication statusPublished - Jan 2023
Externally publishedYes

Research Keywords

  • biomarkers
  • clinical hypothyroidism
  • free thyroxine
  • metabolomics
  • subclinical hypothyroidism
  • thyrotropin
  • Humans
  • Hypothyroidism
  • Thyrotropin
  • Thyroid Hormones
  • Metabolomics
  • Biomarkers
  • Thyroxine

Publisher's Copyright Statement

  • This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

Fingerprint

Dive into the research topics of 'Plasma Metabolomics Reveals Systemic Metabolic Alterations of Subclinical and Clinical Hypothyroidism'. Together they form a unique fingerprint.

Cite this